• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

UPLC-PDA 法同时测定片剂中艾维雷韦、替诺福韦、恩曲他滨和考比司他的含量:用于降解产物的 MS-ESI 研究。

UPLC-PDA Approach for Simultaneous Quantification of Elvitegravir, Tenofovir, Emtricitabine and Cobicistat in Tablets: An MS-ESI Study for Degradation Products.

机构信息

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be University), Gandhi nagar, Rushikonda, Visakhapatnam, Andhra Pradesh 530045, India.

出版信息

J Chromatogr Sci. 2024 Oct 1;62(8):719-731. doi: 10.1093/chromsci/bmad067.

DOI:10.1093/chromsci/bmad067
PMID:37691589
Abstract

A simultaneous ultra-performance liquid chromatography photodiode array detection method was developed and validated for Elvitegravir, Tenofovir and Emtricitabine and Cobicistat drugs in tablet dosage forms. Effective liquid chromatographic quantification was achieved using a Luna C18 (100 × 2.6 mm, 1.6 μ) column with an acetonitrile: 0.1% v/v trifluoro acetic acid (80:20% v/v) mobile phase and a photo diode array detector at 260 nm for a shorter run time of 3 min. The respective retention times for Elvitegravir, Tenofovir, Emtricitabine and Cobicistat were 0.311, 0.792, 1.379 and 2.045 min. The range of linearity was 37.50-225.00, 2.50-15.00, 50.00-300.00 and 37.50-225.00 μg/mL for Elvitegravir, Tenofovir, Emtricitabine and Cobicistat, respectively. A mass spectrometer was employed for quantitative analysis using electron spray ionization multiple reaction monitoring in positive mode. The developed method was validated for different parameters to meet the acceptance criteria as per ICH Q2 (R1) guidelines. Using UPLC-ESI-MS, 12 degradants were identified and their mechanisms were studied.

摘要

建立并验证了一种用于片剂制剂中艾维雷格、替诺福韦和恩曲他滨和考比司他药物的同时超高效液相色谱-光电二极管阵列检测法。采用 Luna C18(100×2.6mm,1.6μm)柱,以乙腈:0.1%v/v 三氟乙酸(80:20%v/v)为流动相,在 260nm 下用光电二极管阵列检测器,可在更短的 3 分钟内实现有效的液相色谱定量。艾维雷格、替诺福韦、恩曲他滨和考比司他的保留时间分别为 0.311、0.792、1.379 和 2.045 分钟。艾维雷格、替诺福韦、恩曲他滨和考比司他的线性范围分别为 37.50-225.00、2.50-15.00、50.00-300.00 和 37.50-225.00μg/mL。采用电喷雾电离多反应监测正模式的质谱仪进行定量分析。该方法经过不同参数的验证,符合 ICH Q2(R1)指南的验收标准。使用 UPLC-ESI-MS,鉴定了 12 种降解产物,并研究了它们的降解机制。

相似文献

1
UPLC-PDA Approach for Simultaneous Quantification of Elvitegravir, Tenofovir, Emtricitabine and Cobicistat in Tablets: An MS-ESI Study for Degradation Products.UPLC-PDA 法同时测定片剂中艾维雷韦、替诺福韦、恩曲他滨和考比司他的含量:用于降解产物的 MS-ESI 研究。
J Chromatogr Sci. 2024 Oct 1;62(8):719-731. doi: 10.1093/chromsci/bmad067.
2
Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.建立并验证人血浆和脑脊液中替诺福韦和替诺福韦艾拉酚胺的 LC-MS/MS 检测方法。
J Pharm Biomed Anal. 2018 Jul 15;156:163-169. doi: 10.1016/j.jpba.2018.04.035. Epub 2018 Apr 23.
3
A Validated Stability Indicating RP-HPLC Method for the Determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir and Cobicistat in Pharmaceutical Dosage Form.一种用于测定药物剂型中恩曲他滨、替诺福韦酯富马酸盐、埃替格韦和考比司他的经验证的稳定性指示反相高效液相色谱法。
J Chromatogr Sci. 2016 May-Jun;54(5):759-64. doi: 10.1093/chromsci/bmw004. Epub 2016 Feb 9.
4
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.艾维雷韦/考比司他/恩曲他滨/替诺福韦酯富马酸单片复方制剂(Stribild®):在成人 HIV-1 感染管理中的应用评价。
Drugs. 2014 Jan;74(1):75-97. doi: 10.1007/s40265-013-0158-4.
5
Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry.采用液相色谱正离子电喷雾串联质谱法同时定量测定血浆中的非核苷类逆转录酶抑制剂依非韦伦、核苷类逆转录酶抑制剂恩曲他滨和核苷酸类逆转录酶抑制剂替诺福韦。
Biomed Chromatogr. 2009 Apr;23(4):371-81. doi: 10.1002/bmc.1125.
6
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.在初治的 HIV 感染青少年中,含有艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺的单片复方制剂的安全性、疗效和药代动力学:一项单臂、开放标签试验。
Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.
7
Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study.富含蛋白质饮料或标准餐对健康日本男性受试者中埃替拉韦、考比司他、恩曲他滨和替诺福韦药代动力学的影响:一项随机、三交叉研究。
J Clin Pharmacol. 2014 Jun;54(6):640-8. doi: 10.1002/jcph.283. Epub 2014 Mar 18.
8
The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards.使用液相色谱-串联质谱法(LC/MS/MS)和同位素标记内标物同时测定血浆中的替诺福韦和恩曲他滨。
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 1;877(20-21):1907-14. doi: 10.1016/j.jchromb.2009.05.029. Epub 2009 May 21.
9
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.在病毒学抑制的 HIV 成人患者中,与继续使用利托那韦增效蛋白酶抑制剂联合恩曲他滨和替诺福韦相比,简化的艾维雷韦/考比司他/恩曲他滨/替诺福韦与恩曲他滨和替诺福韦的联合方案(STRATEGY-PI):一项随机、开放标签、3b 期、非劣效性试验的 48 周结果。
Lancet Infect Dis. 2014 Jul;14(7):581-9. doi: 10.1016/S1473-3099(14)70782-0. Epub 2014 Jun 5.
10
A UPLC method development and validation study of Upadacitinib and its impurities in extended - release oral tablet dosage forms.乌帕替尼及其杂质在缓释口服片剂中的 UPLC 方法开发和验证研究。
Ann Pharm Fr. 2024 Sep;82(5):780-791. doi: 10.1016/j.pharma.2024.03.007. Epub 2024 Mar 28.